Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of ...
Abelacimab, an FXI inhibitor, significantly reduces bleeding risks in patients on antiplatelet therapy compared with rivaroxaban. The AZALEA-TIMI 71 study demonstrated consistent bleeding reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results